Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/190749
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Response kinetics is not well-established as a prognostic marker in multiple myeloma (MM). We developed a mathematical model to assess the prognostic value of serum monoclonal component (MC) response kinetics during 6 induction cycles in 373 newly diagnosed MM patients. The model calculated a resistance parameter that reflects the stagnation in the response after an initial descent, dividing the patients into two kinetics categories with significantly different progression-free survival (PFS). Introduction: Response kinetics is a well-established prognostic marker in acute lymphoblastic leukemia. The situation is not clear in multiple myeloma (MM) despite having a biomarker for response monitoring (monoclonal component [MC]). Materials and Methods: We developed a mathematical model to assess the prognostic value of serum MC response kinetics during 6 induction cycles, in 373 NDMM transplanted patients treated in the GEM2012Menos65 clinical trial. The model calculated a resistance parameter that reflects the stagnation in the response after an initial descent. Results: Two patient subgroups were defined based on low and high resistance, that respectively captured sensitive and refractory kinetics, with progression-free survival (PFS) at 5 years of 72% and 59% (HR 0.64, 95% CI 0.44-0.93; P =.02). Resistance significantly correlated with depth of response measured after consolidation (80.9% CR and 68.4% minimal residual disease negativity in patients with sensitive vs. 31% and 20% in those with refractory kinetics). Furthermore, it modulated the impact of reaching CR after consolidation; thus, within CR patients those with refractory kinetics had significantly shorter PFS than those with sensitive kinetics (median 54 months vs. NR; P =.02). Minimal residual disease negativity abrogated this effect. Our study also questions the benefit of rapid responders compared to late responders (5-year PFS 59.7% vs. 76.5%, respectively [P <.002]). Of note, 85% of patients considered as late responders were classified as having sensitive kinetics. Conclusion: This semi-mechanistic modeling of M-component kinetics could be of great value to identify patients at risk of early treatment failure, who may benefit from early rescue intervention strategies. (C) 2022 The Authors. Published by Elsevier Inc.
Matèries
Matèries (anglès)
Citació
Citació
TAMARIZ AMADOR, Luis esteban, RODRÍGUEZ OTERO, Paula, JIMÉNEZ UBIETO, Ana, ROSIÑOL DACHS, Laura, ORIOL, Albert, RÍOS, Rafael, SUREDA, Anna, BLANCHARD, Maria jesus, HERNÁNDEZ, Miguel teodoro, CABAÑAS PERIANES, Valentin, JARQUE, Isidro, BARGAY, Joan, GIRONELLA, Mercedes, DE ARRIBA, Felipe, PALOMERA, Luis, GONZALEZ MONTES, Yolanda, MARTÍ, Josep m., KRSNIK, Isabel, ARGUIÑANO, José maría, GONZÁLEZ, María esther, CASADO, Luis felipe, GONZÁLEZ RODRIGUEZ, Ana pilar, LÓPEZ ANGLADA, Lucía, PUIG, Noemi, CEDENA, Maria teresa, PAIVA, Bruno, MATEOS, María victoria, SAN MIGUEL, Jesús, LAHUERTA, Juan josé, BLADÉ, J. (joan), TROCÓNIZ, Iñaki f.. Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma. _Clinical Lymphoma Myeloma and Leukemia_. 2022. Vol. 22, núm. 9, pàgs. e844-e852. [consulta: 25 de febrer de 2026]. ISSN: 2152-2669. [Disponible a: https://hdl.handle.net/2445/190749]